Inmarsat’s Velaris Connectivity Solution to Unlock Unlimited Possibilities of Fast-growing UAV Industry
Ground-breaking new offering will safely integrate drones into managed airspace, unlocking new benefits for business and society while making skies cleaner and greener
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005568/en/
Velaris will provide secure communications for commercial UAVs – commonly known as drones – to seamlessly integrate with aircraft in commercial airspace (Graphic: Business Wire)
Inmarsat, the world leader in global mobile satellite communications, today announced the launch of its advanced new Velaris connectivity solution, which is uniquely positioned to serve as a catalyst for the safe and rapid growth of the Unmanned Aerial Vehicles (UAVs) industry.
Powered by the Inmarsat ELERA global satellite network, Velaris will provide secure communications for commercial UAVs – commonly known as drones – to fly beyond visual line of sight (BVLOS) and seamlessly integrate with aircraft in commercial airspace. Backed by military grade cybersecurity, it allows operators to send their UAVs on long distance flights and access various applications, such as real-time monitoring, to ensure safe integration with other air traffic. In addition, Velaris allows a single pilot to remotely operate multiple UAVs at scale, making operations more commercially viable.
Over the next seven years, the commercial UAV market is projected to increase from $2.32 billion in 2021 to $11.29 billion in 2028, marking a compound annual growth rate (CAGR) of 25.39% during this period1. This will have a far-reaching impact on various aspects of business and society, ranging from cargo delivery, urban transport and surveillance to emergency services and disaster relief, including the supply of critical items such as medicine, test kits and food for remote communities.
To support this fast-paced growth, Velaris will unlock unprecedented new digital automation capabilities within the UAV industry, leading to significant advances in safety, productivity, customer service, location access and accuracy, while also reducing the overall cost of operations. Importantly, it will also support the transport of people and goods in an environmentally friendly manner.
Anthony Spouncer, Inmarsat’s Senior Director of UAVs and Unmanned Traffic Management, said: “Commercial UAVs have the potential to revolutionise a vast array of different industries throughout the world. However, to truly unlock their potential on a commercial scale, it is imperative that autonomous vehicles and unmanned aviation are safely and securely integrated into managed commercial airspace. That’s exactly what Velaris, as Inmarsat’s first global UAV connectivity solution, will deliver.
“Inmarsat’s unparalleled experience in air traffic management and aviation safety, combined with our established track record in civil and military UAV communications, ensures that we can support global regulators, air navigation service providers and UAV operators with seamless airspace integration. In addition, thanks to our ambitious and fully-funded technology roadmap, including our brand new ORCHESTRA communications network of the future, Velaris will continue to develop and evolve alongside the UAV industry, remaining its gold standard connectivity solution for decades to come.”
Inmarsat was recently crowned winner at the prestigious Air Traffic Management (ATM) Magazine Awards for its Pop-Up Unmanned Traffic Management (UTM) Platform, developed with Altitude Angel. Furthermore, Inmarsat is well-integrated in the air traffic management industry as a consortium member of Cranfield University’s recently opened Digital Aviation Research and Technology Centre (DARTeC). The company participates in several projects that aim to revolutionise the future of flight, including the UK Government funded Project HEART (Hydrogen Electric and Automated Regional Transportation) – which is developing the country’s first automated, zero carbon regional air transportation network – and Airspace of the Future (AoF) – which focuses on integrating UAV services with the wider UK transport ecosystem.
“We work with our global partner ecosystem to develop UAV terminals that deliver smaller, more cost effective multi datalink solutions,” added Spouncer. “These are optimised for a wide range of use cases so that our customers can always have the highest possible standard of connectivity. I’m pleased to launch Velaris today. Coming soon after the launch of Inmarsat ORCHESTRA and ELERA, this truly emphasises Inmarsat’s long-term commitment to the commercial UAV market.”
ENDS
ABOUT INMARSAT
Inmarsat is the world leader in global, mobile satellite communications. It owns and operates the world’s most diverse global portfolio of mobile telecommunications satellite networks, and holds a multi-layered, global spectrum portfolio, covering L-band, Ka-band and S-band, enabling unparalleled breadth and diversity in the solutions it provides. Inmarsat’s long-established global distribution network includes not only the world’s leading channel partners but also its own strong direct retail capabilities, enabling end to end customer service assurance.
The company has an unrivalled track record of operating the world’s most reliable global mobile satellite telecommunications networks, sustaining business and mission critical safety & operational applications for more than 40 years. It is also a major driving force behind technological innovation in mobile satellite communications, sustaining its leadership through a substantial investment and a powerful network of technology and manufacturing partners.
Inmarsat operates across a diversified portfolio of sectors with the financial resources to fund its business strategy and holds leading positions in the Maritime, Government, Aviation and Enterprise satcoms markets, operating consistently as a trusted, responsive and high-quality partner to its customers across the globe.
For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.
1 Fortune Business Insights Commercial Drone Market, 2021-2028
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005568/en/
Contact information
Contacts for media enquiries:
Jonathan Sinnatt/Matthew Knowles
Corporate Communications
Tel: +44 (0) 7889 605 272 / +44 (0) 7725 475 507
press@inmarsat.com
Robeel Haq
Head of Communications, Inmarsat Aviation
+44 (0)20 7728 1352
robeel.haq@inmarsat.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom